Basic HTML Version
- 6 -
PRO-Kinetic registry
of procedural and restenosis risks. Nonetheless, these studies, as
well as our registry data, demonstrate that, at least in a significant
group of coronary patients, improved safety and intermediate-
term efficacy results are certainly achievable using contemporary
BMS platforms.
Study limitations
Our registry is limited by the following issues: 1) lack of a
randomisation scheme to other BMS or DES counterparts, 2)
retrospective mode of analysis, 3) single centre (albeit two hospitals)
experience, 4) relatively short lesions and low prevalence of LAD
lesions and/or multivessel and bifurcation interventions, and 5) lack
of systematic angiographic follow-up. Moreover, as stated above,
our results should be viewed in the context of the local clinical
practice with ~40% of DES utilisation designed for patients at higher
risk for restenosis. This ‘pattern of use’ would vary between
countries and among centres and may have a major impact on the
clinical results. Thus, our results are not necessarily applicable to all
hospital environments and/or clinical scenarios.
Conclusions
The relatively low MACE and TVR rate that was observed in our
registry indicates that the PRO-Kinetic stent can achieve excellent
clinical performances in a large group of patients. Those
encouraging results may provoke a discussion about the remaining
role of contemporary BMS platforms and the frontiers of these
devices in achieving optimal clinical results, even without the use of
drug preparations.
Acknowledgements
This study was supported by an unrestricted educational grant of
Biotronik Inc., Switzerland.
References
1. Colombo A, Stankovic G, Moses JW. Selection of coronary stents.
J Am Coll Cardiol.
2002;40:1021-33.
2. van Oeveren W. Reduced deposition of blood formed elements and
fibrin onto amorphous silicon carbide coated stainless steel.
Prog Biomed
Res.
1999;2:78-83.
3. O’Neill, WW. Risk of Bleeding after Elective Percutaneous Coronary
Intervention.
New Engl J Med.
2006;355:1058-1060
4. Dahm JB, Williams T, Wolpers HJ, Nordbeck H, Becker J,
Ruppert J. Clinical investigation into the observation that silicon carbide
coating on cobalt chromium stents leads to early differentiating functional
endothelial layer, increased safety and DES like recurrent restenosis rate:
results of the PRO-Heal registry (PRO-Kinetic enhancing rapid in-stent
endothelialisation).
EuroIntervention.
2008;4:502-8.
5. Blanchard D, Battisada D, Urban P, Moseri M, Juergens C, Guyon P,
Nowak B, Tresukos D, Suttorp MJ, Farshid A, Kornowski R, Garcia E,
Yeend R, Nagai H, Paunovic D. A novel ultra –thin bare metal
stent (BMS): results from a worldwide registry.
EuroIntervention.
2007;
3:249-255.
6. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C,
Kereiakes DJ; Driver investigators. Evaluation of the Medtronic
(Driver) cobalt-chromium alloy coronary stent system.
Am J Cardiol.
2005;95:8-12.
7. Kereiakes, DJ, Cox, DA, Hermiller, JB, Midei MG, Bachinsky, WB,
Nukta ED, Leon, MB, Fink, Marin SL, Lansky AJ, for the Guidant Multi-
Link Vision Stent Registry Investigators. Usefulness of a Cobalt Chromium
Coronary Stent Alloy.
Am J Cardiol.
2003;92:463–466.
8. Fort S, Kornowski R, Silber S, Lewis B, Bilodeau L, Almagor Y,
Remortel E, Morice MC, Colombo A, ‘Fused-Gold’ vs. ‘Bare’ stainless steel
NIRflex stents of the same geometric design in diseased native coronary
arteries. Long- term results from the NIR TOP Study.
EuroIntervention.
2007;3:256-261.